Elucidation of gender and individual differences in chemotherapy-induced nausea and vomiting and comprehensive risk factors analysis

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K07179
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: University of Shizuoka
• Principal Investigator: Tsuji Daiki 静岡県立大学, 薬学部, 講師 (90565615)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: 制吐療法 / 化学療法誘発性悪心・嘔吐 / CINV / 遺伝子多型 / ゲノムバイオマーカー / 性差

Outline of Final Research Achievements

In this study, we integrated data from clinical studies on CINV and added data from patients in a newly initiated prospective clinical trial for case collection to examine gender and individual differences in the occurrence of CINV. The study using existing samples and clinical information and two cohorts of prospective clinical trials showed a clear gender difference with higher CINV expression in female patients. The results also suggest that CYP3A4 and TACR1 gene polymorphisms affect individual differences in CINV. In addition, the effects of menopausal status and sex hormone levels on CINV expression in female patients were examined, and it was shown that menopausal status affects nausea expression and that nausea expression is higher in patients with low FSH levels.

Free Research Field

医療薬学、臨床薬理学、臨床腫瘍学

Academic Significance and Societal Importance of the Research Achievements

がん治療においてはプレシジョン医療の観点から治療の個別化に関する医療が急速な進展を見せている。支持療法においても個別化医療の実現が期待されている。本研究は支持療法のなかで最もエビデンスが蓄積されている制吐療法に着目した個別化制吐療法の実現を目指した研究である。本研究により、悪心・嘔吐発現には性差が存在し、遺伝的な素因も関与することが示されており、個別化制吐療法の実現に向けた取り組みの一助となることが期待される。